Phase II Study of TAK228 in Relapsed Lymphoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Sapanisertib (Primary)
- Indications B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 19 Mar 2018 Planned End Date changed from 1 Mar 2022 to 1 Mar 2023.
- 05 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 02 Mar 2017 Planned primary completion date changed from 1 Dec 2021 to 1 Mar 2022.